Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2016

Open Access 01-12-2016 | Research

A comparison of health utility scores calculated using United Kingdom and Canadian preference weights in persons with alzheimer’s disease and their caregivers

Authors: Mingying Fang, Mark Oremus, Jean-Eric Tarride, Parminder Raina, Canadian Willingness-to-pay Study Group

Published in: Health and Quality of Life Outcomes | Issue 1/2016

Login to get access

Abstract

Background

The use of the EQ-5D to asses the economic benefits of health technologies has led to questions about the cross-population transferability of preference weights to calculate health utility scores. The aim of this study is to investigate whether the use of UK and Canadian preference weights will lead to the calculation of different health utility scores in a sample of persons with Alzheimer’s disease (AD) and their primary informal caregivers.

Methods

We recruited 216 patient-caregiver dyads from nine geriatric and memory clinics across Canada. Participants used the EQ-5D-3L to rate their health-related quality-of-life (HRQoL). EQ-5D-3L responses were transformed into health utility scores using UK and Canadian preference weights. The levels of agreement between the two sets of scores were assessed using intraclass correlation coefficients (ICCs). Bland-Altman plots depicted individual-level differences between the two sets of scores. Differences in health utility scores were tested using the Wilcoxon signed rank sum test. A generalized linear model with a gamma distribution was used to examine whether participants’ socio-demographic characteristics were associated with their health utility scores.

Results

The distributions of health utility scores derived from both the UK and Canadian preference weights were skewed to the left. The intraclass correlation coefficient was 0.94 (95 % CI: 0.92, 0.95) for persons with AD and 0.92 (95 % CI: 0.88, 0.94) for the caregivers. The Canadian weights yielded slightly higher median health utility scores than the UK weights for caregivers (median difference: 0.009; 95 % confidence interval: 0.007, 0.013). This finding persisted after stratifying by disease severity. Few socio-demographic characteristics were associated with the two sets of health utility scores.

Conclusions

Health utility scores exhibited small and clinically unimportant differences when calculated with UK versus Canadian preference weights in persons with AD and their caregivers. The original UK and Canadian population samples used to obtain the preference weights valued health states similarly.
Literature
1.
go back to reference Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812–26.CrossRefPubMedPubMedCentral Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812–26.CrossRefPubMedPubMedCentral
2.
go back to reference Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57.CrossRefPubMed Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57.CrossRefPubMed
3.
go back to reference Bowling A.Health-related quality of life: a discussion of the concept, its use and measurement. In Measuring disease: a review of disease-specific quality of life measurement scales. 2nd edition. Buckingham: Open University Press; 1995. p. 1-19. Bowling A.Health-related quality of life: a discussion of the concept, its use and measurement. In Measuring disease: a review of disease-specific quality of life measurement scales. 2nd edition. Buckingham: Open University Press; 1995. p. 1-19.
4.
go back to reference Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006;10:1–160.CrossRef Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006;10:1–160.CrossRef
5.
go back to reference Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen O-P, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006;22:235–41.CrossRefPubMed Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen O-P, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006;22:235–41.CrossRefPubMed
6.
go back to reference Silberfeld M, Rueda S, Krahn M, Naglie G. Content validity for dementia of three generic preference based health related quality of life instruments. Qual Life Res. 2002;11:71–9.CrossRefPubMed Silberfeld M, Rueda S, Krahn M, Naglie G. Content validity for dementia of three generic preference based health related quality of life instruments. Qual Life Res. 2002;11:71–9.CrossRefPubMed
7.
go back to reference Naglie G, Tansey C, Irvine J, Ritvo P, Black SE, Freedman M, Silberfeld M, Krahn M. Utility-based Quality of Life Measures in Alzheimer’s Disease. Qual Life Res. 2006;15:631–43.CrossRefPubMed Naglie G, Tansey C, Irvine J, Ritvo P, Black SE, Freedman M, Silberfeld M, Krahn M. Utility-based Quality of Life Measures in Alzheimer’s Disease. Qual Life Res. 2006;15:631–43.CrossRefPubMed
9.
go back to reference Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS ONE. 2012;7:e31115.CrossRefPubMedPubMedCentral Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS ONE. 2012;7:e31115.CrossRefPubMedPubMedCentral
10.
go back to reference Lien K, Tam VC, Ko YJ, Mittmann N, Cheung MC, Chan KKW. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. Curr Oncol. 2015;22:e443–52.CrossRefPubMedPubMedCentral Lien K, Tam VC, Ko YJ, Mittmann N, Cheung MC, Chan KKW. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. Curr Oncol. 2015;22:e443–52.CrossRefPubMedPubMedCentral
11.
go back to reference Mozzi A, Meregaglia M, Lazzaro C, Tornatore V, Belfiglio M, Fattore G. A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. Clin Outcomes Res. 2016;8:267–74.CrossRef Mozzi A, Meregaglia M, Lazzaro C, Tornatore V, Belfiglio M, Fattore G. A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. Clin Outcomes Res. 2016;8:267–74.CrossRef
12.
go back to reference Oremus M, Tarride J-E, Clayton N, Raina P, Group CW-t-PS. Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights. Value Health. 2014;17:77–83.CrossRefPubMed Oremus M, Tarride J-E, Clayton N, Raina P, Group CW-t-PS. Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights. Value Health. 2014;17:77–83.CrossRefPubMed
13.
go back to reference Nietzel M, Wakefield J. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Contemp Psychol. 1996;41:642–51. Nietzel M, Wakefield J. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Contemp Psychol. 1996;41:642–51.
14.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease Report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease Report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–9.
15.
go back to reference Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4:55–69.CrossRefPubMed Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4:55–69.CrossRefPubMed
16.
go back to reference Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420.CrossRefPubMed Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420.CrossRefPubMed
17.
go back to reference Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327:307–10.CrossRef Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327:307–10.CrossRef
18.
go back to reference Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–32.CrossRefPubMed Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–32.CrossRefPubMed
19.
go back to reference Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International Comparisons in Valuing EQ‐5D Health States: A Review and Analysis. Value Health. 2009;12:11941200.CrossRef Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International Comparisons in Valuing EQ‐5D Health States: A Review and Analysis. Value Health. 2009;12:11941200.CrossRef
20.
go back to reference Bernert S, Fernández A, Haro JM, König HH, Alonso J, Vilagut G, Sevilla-Dedieu C, De Graaf R, Matschinger H, Heider D. Comparison of Different Valuation Methods for Population Health Status Measured by the EQ‐5D in Three European Countries. Value Health. 2009;12:750–8.CrossRefPubMed Bernert S, Fernández A, Haro JM, König HH, Alonso J, Vilagut G, Sevilla-Dedieu C, De Graaf R, Matschinger H, Heider D. Comparison of Different Valuation Methods for Population Health Status Measured by the EQ‐5D in Three European Countries. Value Health. 2009;12:750–8.CrossRefPubMed
21.
go back to reference Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Mak. 2001;21:7–16.CrossRef Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Mak. 2001;21:7–16.CrossRef
22.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedPubMedCentral Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedPubMedCentral
23.
go back to reference Al Sayah F, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, Xie F, Johnson JA. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Qual Life Res. 2015. Epublished ahead of print. Al Sayah F, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, Xie F, Johnson JA. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Qual Life Res. 2015. Epublished ahead of print.
24.
go back to reference Zucchella C, Bartolo M, Bernini S, Picascia M, Sinforiani E. Quality of life in Alzheimer disease: a comparison of patients’ and caregivers’ points of view. Alzheimer Dis Assoc Disord. 2015;29:50–4.CrossRefPubMed Zucchella C, Bartolo M, Bernini S, Picascia M, Sinforiani E. Quality of life in Alzheimer disease: a comparison of patients’ and caregivers’ points of view. Alzheimer Dis Assoc Disord. 2015;29:50–4.CrossRefPubMed
25.
go back to reference Naglie G, Hogan DB, Krahn M, Beattie BL, Black SE, Macknight C, Freedman M, Patterson C, Borrie M, Bergman H, Byszewski A, Streiner D, Irvine J, Ritvo P, Comrie J, Kowgier M, Tomlinson G. Predictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer’s Disease Quality of Life Study. Am J Geriatr Psychiatr. 2011;19:881–90.CrossRef Naglie G, Hogan DB, Krahn M, Beattie BL, Black SE, Macknight C, Freedman M, Patterson C, Borrie M, Bergman H, Byszewski A, Streiner D, Irvine J, Ritvo P, Comrie J, Kowgier M, Tomlinson G. Predictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer’s Disease Quality of Life Study. Am J Geriatr Psychiatr. 2011;19:881–90.CrossRef
26.
go back to reference Trigg R, Jones RW, Knapp M, King D, Lacey LA, DADE-2 Investigator Groups. The relationship between changes in quality of life outcomes and progression of Alzheimer’s disease: results from the Dependence in AD in England 2 Longitudinal Study. Int J Geriatr Psychiatry. 2015;30:400–8.CrossRefPubMed Trigg R, Jones RW, Knapp M, King D, Lacey LA, DADE-2 Investigator Groups. The relationship between changes in quality of life outcomes and progression of Alzheimer’s disease: results from the Dependence in AD in England 2 Longitudinal Study. Int J Geriatr Psychiatry. 2015;30:400–8.CrossRefPubMed
27.
go back to reference Serrano-Aguilar PG, Lopez-Bastida J, Yanes-Lopez V. Impact on health-related quality of life and perceived burden of informal caregivers of individuals with Alzheimer’s disease. Neuroepidemiology. 2006;27:136–42.CrossRefPubMed Serrano-Aguilar PG, Lopez-Bastida J, Yanes-Lopez V. Impact on health-related quality of life and perceived burden of informal caregivers of individuals with Alzheimer’s disease. Neuroepidemiology. 2006;27:136–42.CrossRefPubMed
28.
go back to reference Abdollahpour I, Nedjat S, Salimi Y, Noroozian M, Majdzadeh R. Which variable is the strongest adjusted predictor of quality of life in caregivers of patients with dementia? Psychogeriatrics. 2015;15:51–7.CrossRefPubMed Abdollahpour I, Nedjat S, Salimi Y, Noroozian M, Majdzadeh R. Which variable is the strongest adjusted predictor of quality of life in caregivers of patients with dementia? Psychogeriatrics. 2015;15:51–7.CrossRefPubMed
29.
go back to reference Zarit SH, Orr NK, Zarit JM. The Hidden Victims of Alzheimer’s Disease: Families Under Stress. New York: New York University Press; 1985. Zarit SH, Orr NK, Zarit JM. The Hidden Victims of Alzheimer’s Disease: Families Under Stress. New York: New York University Press; 1985.
30.
go back to reference Crespo M, Hornillos C, Gomez MM. Assessing quality of life of nursing home residents with dementia: feasibility and limitations in patients with severe cognitive impairment. Int Psychogeriatr. 2013;25:1687–95.CrossRefPubMed Crespo M, Hornillos C, Gomez MM. Assessing quality of life of nursing home residents with dementia: feasibility and limitations in patients with severe cognitive impairment. Int Psychogeriatr. 2013;25:1687–95.CrossRefPubMed
31.
go back to reference Woods RT, Nelis SM, Martyr A, Roberts J, Whitaker CJ, Markova I, Roth I, Morris R, Clare L. What contributes to a good quality of life in early dementia? Awareness and the QoL-AD: a cross-sectional study. Health Qual Life Outcomes. 2014;12:94.CrossRefPubMedPubMedCentral Woods RT, Nelis SM, Martyr A, Roberts J, Whitaker CJ, Markova I, Roth I, Morris R, Clare L. What contributes to a good quality of life in early dementia? Awareness and the QoL-AD: a cross-sectional study. Health Qual Life Outcomes. 2014;12:94.CrossRefPubMedPubMedCentral
32.
go back to reference Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes. 2014;12:74.CrossRefPubMedPubMedCentral Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes. 2014;12:74.CrossRefPubMedPubMedCentral
33.
go back to reference Tarride JE, Oremus M, Pullenayegum E, Clayton N, Raina P. How does the Canadian general public rate moderate Alzheimer’s disease? J Aging Res. 2011;20:682470. Tarride JE, Oremus M, Pullenayegum E, Clayton N, Raina P. How does the Canadian general public rate moderate Alzheimer’s disease? J Aging Res. 2011;20:682470.
34.
go back to reference Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38:115–21.CrossRefPubMed Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38:115–21.CrossRefPubMed
Metadata
Title
A comparison of health utility scores calculated using United Kingdom and Canadian preference weights in persons with alzheimer’s disease and their caregivers
Authors
Mingying Fang
Mark Oremus
Jean-Eric Tarride
Parminder Raina
Canadian Willingness-to-pay Study Group
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2016
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-016-0510-y

Other articles of this Issue 1/2016

Health and Quality of Life Outcomes 1/2016 Go to the issue